Company profile

Beckman Coulter (Danaher)

Named as a key player in 198 of our reports, across 33 regions and countries.

[1] ClinicalTrials.gov, Studies led by Beckman Coulter (Danaher) or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Where they show up

198 reports

Our reports that name Beckman Coulter (Danaher) as a key player, by category and place.

  • Medical Devices · 198

Places 33

Beckman Coulter (Danaher)'s markets

6

Markets where they are a key player. Each opens the market's statistics for every place we cover.

Recent reports naming Beckman Coulter (Danaher)

Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.

All 198 reports

Companies they compete with most

Named as key players in the same markets as Beckman Coulter (Danaher) (number of shared markets).

Siemens Healthineers4 shared markets Abbott Laboratories3 shared markets Roche Diagnostics3 shared markets BD (Becton, Dickinson)2 shared markets bioMérieux SA2 shared markets Sysmex Corporation2 shared markets Accelerate Diagnostics, Inc.1 shared market ARKRAY1 shared market
Public data

Free public data on Beckman Coulter (Danaher)

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Home country
United States
Legal name
BECKMAN COULTER, INC.
Type
Medicines

Source: Wikidata, Company record Q479952. Retrieved 13 Nov 2026.

Source: GLEIF, Legal entity record, LEI 5493008CNCZVRJ77MV44. Retrieved 13 Nov 2026.

Trials over time

Studies Beckman Coulter (Danaher) leads, by the year they started and their phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Beckman Coulter (Danaher) or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Also active in

Markets we cover where free public records show Beckman Coulter (Danaher): trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Topics

The topics of the markets Beckman Coulter (Danaher) is in.

All topics

From our blog

Stories on the topics Beckman Coulter (Danaher) works in.

All stories

Dermatology Diagnostics: AI and Skin Health

Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…

Read

Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed

TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…

Read

Healthcare In-Vitro Diagnostics: What Comes After COVID

COVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…

Read

Search all reports for Beckman Coulter (Danaher) All companies